TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux
Authors
Keywords
-
Journal
BIOPHARMACEUTICS & DRUG DISPOSITION
Volume 37, Issue 7, Pages 397-408
Publisher
Wiley
Online
2016-07-15
DOI
10.1002/bdd.2022
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Whole-Body Physiologically Based Pharmacokinetic Model of Gefitinib in Mice and Scale-Up to Humans
- (2015) Youwei Bi et al. AAPS Journal
- Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib
- (2015) John F. Deeken et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Ingredients in Fruit Juices Interact with Dasatinib Through Inhibition of BCRP: A New Mechanism of Beverage-Drug Interaction
- (2015) Brett Fleisher et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines
- (2015) Maricla Galetti et al. PLoS One
- Enzyme-Transporter-Mediated Drug Interactions with Small Molecule Tyrosine Kinase Inhibitors
- (2014) Jie Shao et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- ABC Transporters in Multi-Drug Resistance and ADME-Tox of Small Molecule Tyrosine Kinase Inhibitors
- (2014) Jiexin Deng et al. PHARMACEUTICAL RESEARCH
- Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide
- (2013) E. I. Zimmerman et al. CLINICAL CANCER RESEARCH
- Overview of P-glycoprotein inhibitors: a rational outlook
- (2012) Kale Mohana Raghava Srivalli et al. Brazilian Journal of Pharmaceutical Sciences
- Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models
- (2012) Amit K. Tiwari et al. CANCER LETTERS
- Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance
- (2012) Suneet Shukla et al. DRUG RESISTANCE UPDATES
- Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib
- (2012) Mukul Minocha et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Reversing multidrug resistance by tyrosine kinase inhibitors
- (2012) Miao He et al. Chinese Journal of Cancer
- The Challenge of Exploiting ABCG2 in the Clinic
- (2011) Robert W. Robey et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Interactions of Tyrosine Kinase Inhibitors with Organic Cation Transporters and Multidrug and Toxic Compound Extrusion Proteins
- (2011) T. Minematsu et al. MOLECULAR CANCER THERAPEUTICS
- Mechanisms of acquired resistance to tyrosine kinase inhibitors
- (2011) Yi-fan Chen et al. Acta Pharmaceutica Sinica B
- Differences in the expression of endogenous efflux transporters in MDR1-transfected versus wildtype cell lines affect P-glycoprotein mediated drug transport
- (2010) Konstantin Kuteykin-Teplyakov et al. BRITISH JOURNAL OF PHARMACOLOGY
- Tyrosine Kinase Inhibitor Gefitinib Enhances Topotecan Penetration of Gliomas
- (2010) Angel M. Carcaboso et al. CANCER RESEARCH
- Role of ATP-Binding Cassette and Solute Carrier Transporters in Erlotinib CNS Penetration and Intracellular Accumulation
- (2010) M. A. Elmeliegy et al. CLINICAL CANCER RESEARCH
- Interaction of Tyrosine Kinase Inhibitors with the MDR-Related ABC Transporter Proteins
- (2010) Xiao-Kun Wang et al. CURRENT DRUG METABOLISM
- Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy
- (2010) J Rafael Sierra et al. Molecular Cancer
- Nilotinib (AMN107, Tasigna ® ) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters
- (2009) Amit K. Tiwari et al. BIOCHEMICAL PHARMACOLOGY
- The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors
- (2009) Krupa J Patel et al. BMC CANCER
- Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties
- (2009) C Hegedűs et al. BRITISH JOURNAL OF PHARMACOLOGY
- Clinical pharmacokinetics of tyrosine kinase inhibitors
- (2009) Nielka P. van Erp et al. CANCER TREATMENT REVIEWS
- Phase I and Pharmacokinetic Studies of Erlotinib Administered Concurrently with Radiotherapy for Children, Adolescents, and Young Adults with High-Grade Glioma
- (2009) A. Broniscer et al. CLINICAL CANCER RESEARCH
- Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment
- (2009) J. S. Lagas et al. CLINICAL CANCER RESEARCH
- A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors
- (2009) G. D. Demetri et al. CLINICAL CANCER RESEARCH
- Tyrosine Kinase Inhibitor Enhances the Bioavailability of Oral Irinotecan in Pediatric Patients With Refractory Solid Tumors
- (2009) Wayne L. Furman et al. JOURNAL OF CLINICAL ONCOLOGY
- Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia
- (2008) A. Giannoudis et al. BLOOD
- Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications
- (2008) D. K. Hiwase et al. CLINICAL CANCER RESEARCH
- The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME–Tox)
- (2008) Gergely Szakács et al. DRUG DISCOVERY TODAY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now